HEX
Server: Apache
System: Linux zacp120.webway.host 4.18.0-553.50.1.lve.el8.x86_64 #1 SMP Thu Apr 17 19:10:24 UTC 2025 x86_64
User: govancoz (1003)
PHP: 8.3.26
Disabled: exec,system,passthru,shell_exec,proc_close,proc_open,dl,popen,show_source,posix_kill,posix_mkfifo,posix_getpwuid,posix_setpgid,posix_setsid,posix_setuid,posix_setgid,posix_seteuid,posix_setegid,posix_uname
Upload Files
File: //home/govancoz/mail/new/1761377429.M736385P1338223.zacp120.webway.host,S=8312,W=8400
Return-Path: <aaa@e-secure-it.com>
Delivered-To: govancoz@zacp120.webway.host
Received: from zacp120.webway.host
	by zacp120.webway.host with LMTP
	id kN7QKZV8/GhvaxQA8rC0kQ
	(envelope-from <aaa@e-secure-it.com>)
	for <govancoz@zacp120.webway.host>; Sat, 25 Oct 2025 09:30:29 +0200
Return-path: <aaa@e-secure-it.com>
Envelope-to: cheryl@govan.co.za
Delivery-date: Sat, 25 Oct 2025 09:30:29 +0200
Received: from mail.e-secure-it.com ([77.222.85.140]:35830 helo=server.e-secure-it.com)
	by zacp120.webway.host with esmtps  (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
	(Exim 4.98.2)
	(envelope-from <aaa@e-secure-it.com>)
	id 1vCYjO-00000005ahi-00D3
	for cheryl@govan.co.za;
	Sat, 25 Oct 2025 09:30:29 +0200
Received: from ws-dip-gc02.diplomat.com.mt (c155-179.i01-7.onvol.net [212.56.155.179])
	by server.e-secure-it.com (Postfix) with ESMTPSA id DDAA32AD0367;
	Wed, 22 Oct 2025 17:18:10 +0200 (CEST)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=e-secure-it.com;
	s=default; t=1761146294;
	bh=2Twpq7m2mjlUBarC03FkVVrvDUPvHutQRv/ZPOsCuBs=; l=2426;
	h=Content-Type:MIME-Version:Subject:To:From:Date:Reply-To;
	b=qAg+Q8QfDvGaXflE/E4h/6aoGoSCBPU+mMjjeyfp+dvmOWaPFTxzfNvZyFbm5OPhc
	 h4c/3ltSMV5VbWoXOJ8eViXGpHstmQPlTSRtdHCp9WvYKozQ25IjlvK355tTTszF7X
	 Q87BvJ4JdFTZmUBXiTwENI/zj5AMS5USNwItAWrg=
Content-Type: multipart/alternative; boundary="===============0622001340=="
MIME-Version: 1.0
Subject: Proposal for Strategic Business Collaboration.
To: Recipients <aaa@e-secure-it.com>
From: "Dr. Shingo Iwamoto" <aaa@e-secure-it.com>
Date: Wed, 22 Oct 2025 16:54:25 +0200
Reply-To: drshingoiwamotopharm1@gmail.com
X-Spam-Status: No, score=1.8
X-Spam-Score: 18
X-Spam-Bar: +
X-Ham-Report: =?ISO-8859-1?Q?Spam_detection_software=2C_running_on_the_system_=22zacp120=2Ewebway?= =?ISO-8859-1?Q?=2Ehost=22=2C=0A_has_NOT_identified_this_incoming_ema?= =?ISO-8859-1?Q?il_as_spam=2E__The_original=0A_message_has_been_attac?= =?ISO-8859-1?Q?hed_to_this_so_you_can_view_it_or_label=0A_similar_fu?= =?ISO-8859-1?Q?ture_email=2E__If_you_have_any_questions=2C_see=0A_ro?= =?ISO-8859-1?Q?ot=5C=40localhost_for_details=2E=0A_Content_preview=3A_?= =?ISO-8859-1?Q?_Dear_Esteemed_Professional=2C_I_hope_this_message_fi?= =?ISO-8859-1?Q?nds_you=0A___well=2E_Nichi-Iko_Pharmaceutical_Co=2E=2C?= =?ISO-8859-1?Q?_Ltd=2E=2C_a_leading_pharmaceutical_manufacturer=0A__?= =?ISO-8859-1?Q?__based_in_Japan=2C_is_currently_seeking_a_qualified_?= =?ISO-8859-1?Q?individual_to_=5B=2E=2E=2E=5D_=0A_Content_analysis_de?= =?ISO-8859-1?Q?tails=3A___=281=2E8_points=2C_5=2E0_required=29=0A__p?= =?ISO-8859-1?Q?ts_rule_name______________description=0A_----_-------?= =?ISO-8859-1?Q?---------------_-------------------------------------?= =?ISO-8859-1?Q?-------------=0A__0=2E0_URIBL=5FBLOCKED__________ADMI?= =?ISO-8859-1?Q?NISTRATOR_NOTICE=3A_The_query_to_URIBL_was_blocked=2E=0A?= =?ISO-8859-1?Q?_____________________________See=0A__________________?= =?ISO-8859-1?Q?___________http=3A//wiki=2Eapache=2Eorg/spamassassin/?= =?ISO-8859-1?Q?DnsBlocklists#dnsbl-block=0A_________________________?= =?ISO-8859-1?Q?_____for_more_information=2E=0A______________________?= =?ISO-8859-1?Q?_______=5BURI=3A_e-secure-it=2Ecom=5D=0A__0=2E0_RCVD=5FI?= =?ISO-8859-1?Q?N=5FVALIDITY=5FCERTIFIED=5FBLOCKED_RBL=3A_ADMINISTRAT?= =?ISO-8859-1?Q?OR_NOTICE=3A_The=0A_____________________________query?= =?ISO-8859-1?Q?_to_Validity_was_blocked=2E__See=0A__________________?= =?ISO-8859-1?Q?___________https=3A//knowledge=2Evalidity=2Ecom/hc/en?= =?ISO-8859-1?Q?-us/articles/20961730681243=0A_______________________?= =?ISO-8859-1?Q?_______for_more_information=2E=0A____________________?= =?ISO-8859-1?Q?______=5B77=2E222=2E85=2E140_listed_in_sa-trusted=2Eb?= =?ISO-8859-1?Q?ondedsender=2Eorg=5D=0A__0=2E0_RCVD=5FIN=5FVALIDITY=5FR?= =?ISO-8859-1?Q?PBL=5FBLOCKED_RBL=3A_ADMINISTRATOR_NOTICE=3A_The_quer?= =?ISO-8859-1?Q?y_to=0A______________________________Validity_was_blo?= =?ISO-8859-1?Q?cked=2E__See=0A_____________________________https=3A/?= =?ISO-8859-1?Q?/knowledge=2Evalidity=2Ecom/hc/en-us/articles/2096173?= =?ISO-8859-1?Q?0681243=0A______________________________for_more_info?= =?ISO-8859-1?Q?rmation=2E=0A_____________________________=5B77=2E222?= =?ISO-8859-1?Q?=2E85=2E140_listed_in_bl=2Escore=2Esenderscore=2Ecom=5D=0A?= =?ISO-8859-1?Q?__0=2E0_RCVD=5FIN=5FVALIDITY=5FSAFE=5FBLOCKED_RBL=3A_?= =?ISO-8859-1?Q?ADMINISTRATOR_NOTICE=3A_The_query_to=0A______________?= =?ISO-8859-1?Q?________________Validity_was_blocked=2E__See=0A______?= =?ISO-8859-1?Q?_______________________https=3A//knowledge=2Evalidity?= =?ISO-8859-1?Q?=2Ecom/hc/en-us/articles/20961730681243=0A___________?= =?ISO-8859-1?Q?___________________for_more_information=2E=0A________?= =?ISO-8859-1?Q?_____________________=5B77=2E222=2E85=2E140_listed_in?= =?ISO-8859-1?Q?_sa-accredit=2Ehabeas=2Ecom=5D=0A_-0=2E0_SPF=5FPASS__?= =?ISO-8859-1?Q?_____________SPF=3A_sender_matches_SPF_record=0A_-0=2E1?= =?ISO-8859-1?Q?_DKIM=5FVALID=5FEF__________Message_has_a_valid_DKIM_?= =?ISO-8859-1?Q?or_DK_signature_from=0A_____________________________e?= =?ISO-8859-1?Q?nvelope-from_domain=0A_-0=2E1_DKIM=5FVALID=5FAU______?= =?ISO-8859-1?Q?____Message_has_a_valid_DKIM_or_DK_signature_from_aut?= =?ISO-8859-1?Q?hor's=0A_____________________________domain=0A__0=2E1?= =?ISO-8859-1?Q?_DKIM=5FSIGNED____________Message_has_a_DKIM_or_DK_si?= =?ISO-8859-1?Q?gnature=2C_not_necessarily_valid=0A_-0=2E1_DKIM=5FVAL?= =?ISO-8859-1?Q?ID_____________Message_has_at_least_one_valid_DKIM_or?= =?ISO-8859-1?Q?_DK_signature=0A__0=2E2_FREEMAIL=5FREPLYTO=5FEND=5FDI?= =?ISO-8859-1?Q?GIT_Reply-To_freemail_username_ends_in_digit=0A______?= =?ISO-8859-1?Q?_______________________=5Bdrshingoiwamotopharm1=28at=29g?= =?ISO-8859-1?Q?mail=2Ecom=5D=0A__0=2E0_HTML=5FMESSAGE___________BODY?= =?ISO-8859-1?Q?=3A_HTML_included_in_message=0A__1=2E8_FREEMAIL=5FFOR?= =?ISO-8859-1?Q?GED=5FREPLYTO_Freemail_in_Reply-To=2C_but_not_From?=
X-Spam-Flag: NO

You will not see this in a MIME-aware mail reader.
--===============0622001340==
Content-Type: text/plain; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body

Dear Esteemed Professional,
 I hope this message finds you well.
 Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer =
based in Japan, is currently seeking a qualified individual to serve as our=
 official representative in South Africa. This role involves managing miner=
al procurement and overseeing the establishment of our annex office in Sout=
h Africa under a five-year contractual agreement.
 This is a strategic opportunity to represent a respected global brand and =
play a key role in expanding our international presence. We are offering a =
competitive compensation package along with decision-making autonomy.
 If you are interested in learning more, kindly respond to this message for=
 further details.
 Warm regards,
Dr. Shingo Iwamoto
President & CEO
Nichi-Iko Pharmaceutical Co., Ltd.
5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, Japan

--===============0622001340==
Content-Type: text/html; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body

<HTML><head><meta http-equiv=3D"Content-Type" content=3D"text/html; charset=
=3Diso-8859-1"/></head><BODY><P>Dear Esteemed Professional,</P>
<P>I hope this message finds you well.</P>
<P>Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacture=
r based in Japan, is currently seeking a qualified individual to serve as o=
ur official representative in South Africa. This role involves managing min=
eral procurement and overseeing the establishment of our annex office in So=
uth Africa under a five-year contractual agreement.</P>
<P>This is a strategic opportunity to represent a respected global brand an=
d play a key role in expanding our international presence. We are offering =
a competitive compensation package along with decision-making autonomy.</P>
<P>If you are interested in learning more, kindly respond to this message f=
or further details.</P>
<P>Warm regards,<BR>Dr. Shingo Iwamoto<BR>President &amp; CEO<BR>Nichi-Iko =
Pharmaceutical Co., Ltd.<BR>5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, =
Japan</P></BODY></HTML>
--===============0622001340==--